However, the long-term benefits of improved glycemic control, weight reduction, and potential cardiovascular benefits may justify the investment in semaglutide for many patients
GHK-Cu is a copper-complexed tripeptide (Gly-His-Lys) naturally present in human plasma and other biological fluids
The difference usually comes down to dosage and FDA approval
When looking at the percentage of participants that dropped out of the trial due to adverse effects, 2-6% of patients in the cagrilintide group discontinued treatment early while 7% of the participants receiving liraglutide discontinued treatment early, These findings were in comparison to only 3% of test subjects from the placebo group that discontinued treatment due to adverse events [1]
The unit calculations will be different for each medication even if you use the same syringe size
The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours)